STOCK TITAN

Adagio Medical Holdings (ADGM) awards 30,000 stock options to board director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Adagio Medical Holdings, Inc. reported that director Keyvan Mirsaeedi-Farahani received a grant of 30,000 non-qualified stock options on June 16, 2026. The options have an exercise price of $0.7103 per share and expire on June 16, 2036. They were granted under the company’s Non-Employee Director Compensation Policy and 2024 Equity Incentive Plan and will vest in 12 equal monthly installments over one year starting from the vesting commencement date of June 16, 2026. After this grant, the reporting person holds 30,000 options directly.

Positive

  • None.

Negative

  • None.
Insider Mirsaeedi-Farahani Keyvan
Role Director
Type Security Shares Price Value
Grant/Award Non-qualified stock option (right to buy) F1 30,000 $0.00 $0.00
Holdings After Transaction: Non-qualified stock option (right to buy) — 30,000 shares (Direct)
Footnotes (1)
  1. F1. Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026.
Options Granted 30,000 options Non-qualified stock option grant to director on June 16, 2026
Exercise Price $0.7103 per share Conversion or exercise price of the stock options
Expiration Date June 16, 2036 Expiration of the non-qualified stock option grant
Post-grant Holdings 30,000 options Total options held directly by the reporting person after the grant
Vesting Schedule 1/12 monthly over one year Monthly vesting after June 16, 2026 vesting commencement date
Non-qualified stock option financial
"Non-qualified stock option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Equity Incentive Plan financial
"under the Issuer's ... 2024 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Non-Employee Director Compensation Policy financial
"under the Issuer's Non-Employee Director Compensation Policy"
vesting commencement date financial
"after the vesting commencement date of 06/16/2026"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

What did Adagio Medical Holdings (ADGM) report in this Form 4 for Keyvan Mirsaeedi-Farahani?

Adagio Medical Holdings reported that director Keyvan Mirsaeedi-Farahani received a grant of 30,000 non-qualified stock options on June 16, 2026. These options are part of director compensation and were awarded at an exercise price of $0.7103 per share.

What are the key terms of the 30,000 stock options granted by ADGM?

The grant consists of 30,000 non-qualified stock options with an exercise price of $0.7103 per share and an expiration date of June 16, 2036. The options relate to the company’s common stock and are held directly by the reporting person.

How do the ADGM stock options granted to Mirsaeedi-Farahani vest?

The options will vest in 12 equal monthly installments over a one-year period. Specifically, 1/12 of the shares underlying the option vests at the end of each month of continuous service after the vesting commencement date of June 16, 2026.

Under which plans were the ADGM options to Mirsaeedi-Farahani granted?

The 30,000 options were granted under Adagio Medical Holdings’ Non-Employee Director Compensation Policy and its 2024 Equity Incentive Plan. These frameworks govern equity-based compensation for non-employee directors of the company.

What is Mirsaeedi-Farahani’s reported holdings after this ADGM option grant?

Following the reported grant, the filing states that Mirsaeedi-Farahani holds 30,000 stock options directly. These options are all tied to the June 16, 2026 grant and are subject to the specified vesting schedule and June 16, 2036 expiration date.

Is the ADGM Form 4 transaction a market purchase or sale of shares?

No market purchase or sale was reported. The Form 4 describes a grant of 30,000 non-qualified stock options as compensation, coded as a grant or award acquisition, with an exercise price of $0.7103 per share and no cash transaction disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mirsaeedi-Farahani Keyvan

(Last)(First)(Middle)
C/O ADAGIO MEDICAL HOLDINGS, INC.
26051 MERIT CIRCLE, SUITE 102

(Street)
LAGUNA HILLS CALIFORNIA 92653

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Adagio Medical Holdings, Inc. [ ADGM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified stock option (right to buy)(1)$0.710306/16/2026A30,000 (1)06/16/2036Common Stock30,000$030,000D
Explanation of Responses:
1. Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026.
/s/ Deborah Kaster, Attorney-in-Fact08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)